PR Newswire (paid press release):
EXTON, Pa., Nov. 29, 2017 /PRNewswire/ — At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, a figure on par with uptake of Taltz at a similar post-launch fielding time. Current users of the IL-23 inhibitor cite that they…
TravelWireNews Chatroom for Readers (join us)
Click here to read the full article.